Prospective observational study molecular tumor board of the Comprehensive Cancer Center Mainfranken of the University Hospital of Würzburg
Recruiting
- Conditions
- C00-C97Malignant neoplasms
- Registration Number
- DRKS00029051
- Lead Sponsor
- niversitätsklinikum Würzburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 998
Inclusion Criteria
Recommendation in the organ tumor board for a discussion in the molecular tumor board
- Guideline-based and evidence-based therapy already exhausted or to be exhausted in the foreseeable future
- Molecular genetic findings with unclear relevance
- Results of routine diagnostics not sufficiently informative
Exclusion Criteria
- Lack of ability to give consent or informed consent for registry study.
- Lack of consent for tissue and data release and lack of consent for genetic testing/panel diagnostics.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary aim of the study is to provide insights into the following points by means of a systematic and structured recording and evaluation of MTB cases in Würzburg: <br>- Characteristics of the patients* presented<br>- Frequency/type of diagnostic methods used<br>- Frequency/type/relevance of molecular-genetic alterations detected<br>- frequency/type of therapy recommendations and their implementation<br>- further course of treatment of the patients
- Secondary Outcome Measures
Name Time Method The secondary aim of the study is to generate initial evidence for the following questions: <br>- Which patient groups benefit from molecular genetic testing?<br>- Which biomarkers are relevant and targetable?<br>- How effective are the recommended therapies?